Brokerages Set Beam Therapeutics Price Target at $49.36

Analysts see potential in the biotech firm's base editing platform for genetic medicines.

Apr. 19, 2026 at 8:35am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, high-tech laboratory equipment and tools used in genetic engineering, with a focus on the textures, shapes, and dramatic lighting that convey a sense of precision and scientific innovation.Beam Therapeutics' pioneering base editing technology is driving optimism about the company's potential to develop novel genetic therapies.Cambridge Today

Beam Therapeutics Inc. (NASDAQ:BEAM) has received an average 'Moderate Buy' rating from 16 research firms covering the stock, with a consensus price target of $49.36. The Cambridge, Massachusetts-based biotech company is developing precision genetic medicines using its pioneering base editing technology.

Why it matters

Beam's base editing platform offers the potential to precisely correct or disrupt disease-causing genetic variants, which could lead to novel therapies for areas with significant unmet medical need. The company's strong research and development progress, as reflected in the analysts' price targets, signals optimism about Beam's future growth prospects in the rapidly evolving field of genetic medicine.

The details

Beam Therapeutics received a 'Moderate Buy' rating from the 16 research firms covering the stock. One analyst issued a 'sell' recommendation, three gave 'hold' ratings, 11 recommended 'buy', and one issued a 'strong buy'. The average 12-month price target among the analysts is $49.36. Several firms, including UBS, Citigroup, and Sanford C. Bernstein, have raised their price targets on Beam Therapeutics in recent months, reflecting confidence in the company's base editing technology and pipeline development.

  • Beam Therapeutics went public in February 2020.
  • The company reported its latest quarterly earnings on February 24, 2026.

The players

Beam Therapeutics Inc.

A biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia.

UBS Group

A global investment bank and financial services firm that initiated coverage on Beam Therapeutics in January 2026.

Citigroup

A multinational investment bank and financial services corporation that raised its price target on Beam Therapeutics in March 2026.

Sanford C. Bernstein

A research and investment management firm that raised its price target on Beam Therapeutics in January 2026.

Got photos? Submit your photos here. ›

What’s next

Beam Therapeutics is expected to continue advancing its pipeline of genetic medicine candidates using its base editing platform. Investors will closely monitor the company's progress in clinical trials and regulatory approvals in the coming years.

The takeaway

Beam Therapeutics' promising base editing technology and strong research and development progress have garnered the attention of Wall Street analysts, who see significant growth potential for the company in the rapidly evolving field of genetic medicine.